{"id":39248,"date":"2025-08-13T16:13:30","date_gmt":"2025-08-13T08:13:30","guid":{"rendered":"https:\/\/flcube.com\/?p=39248"},"modified":"2025-08-13T16:13:30","modified_gmt":"2025-08-13T08:13:30","slug":"canbridge-pharmaceuticals-secures-hk-100-million-equity-financing-from-baheal-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39248","title":{"rendered":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma"},"content":{"rendered":"\n

CANbridge Pharmaceuticals (HKG: 1228<\/a>) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015<\/a>). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge’s commercial operations and strengthen its market capabilities.<\/p>\n\n\n\n

Strategic Equity Financing<\/strong>
The equity financing is designed to enhance CANbridge’s commercial infrastructure and capabilities. The funds will be utilized to advance the company’s commercial objectives and reinforce its position in the rare disease market.<\/p>\n\n\n\n

Commercial Services Agreement<\/strong>
In addition to the equity investment, CANbridge and Baheal Pharma have signed an exclusive commercial services agreement. Under this agreement, a subsidiary of Baheal Pharma will act as the exclusive commercial service provider for certain CANbridge products in mainland China, Hong Kong, and Macau. An affiliate of Baheal Pharma also has the option to serve as a distributor in these regions.<\/p>\n\n\n\n

Expected Outcomes<\/strong>
This collaboration and equity investment are expected to solidify CANbridge’s leading position in the domestic rare disease market. The partnership leverages Baheal Pharma’s commercial expertise and market presence to expand CANbridge’s product reach and enhance its commercial performance.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a…<\/p>\n","protected":false},"author":1,"featured_media":39251,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[288,142,19,883,24,2011],"class_list":["post-39248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-baheal-pharmaceutical","tag-canbridge-pharmaceuticals","tag-cro-cmo-cdmo","tag-hkg-1228","tag-rare-orphan-disease-drugs","tag-she-301015"],"yoast_head":"\nCANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma\" \/>\n<meta property=\"og:description\" content=\"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39248\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T08:13:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma\",\"datePublished\":\"2025-08-13T08:13:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1310.webp\",\"keywords\":[\"Baheal Pharmaceutical\",\"CANbridge Pharmaceuticals\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 1228\",\"Rare \\\/ orphan disease drugs\",\"SHE: 301015\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39248#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39248\",\"name\":\"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1310.webp\",\"datePublished\":\"2025-08-13T08:13:30+00:00\",\"description\":\"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39248\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1310.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1310.webp\",\"width\":1080,\"height\":608,\"caption\":\"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma - Insight, China's Pharmaceutical Industry","description":"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39248","og_locale":"en_US","og_type":"article","og_title":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma","og_description":"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.","og_url":"https:\/\/flcube.com\/?p=39248","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-13T08:13:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39248#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39248"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma","datePublished":"2025-08-13T08:13:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39248"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","keywords":["Baheal Pharmaceutical","CANbridge Pharmaceuticals","CRO \/ CMO \/ CDMO","HKG: 1228","Rare \/ orphan disease drugs","SHE: 301015"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39248#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39248","url":"https:\/\/flcube.com\/?p=39248","name":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39248#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","datePublished":"2025-08-13T08:13:30+00:00","description":"CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge's commercial operations and strengthen its market capabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39248"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39248#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","width":1080,"height":608,"caption":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1310.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39248"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39248\/revisions"}],"predecessor-version":[{"id":39252,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39248\/revisions\/39252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39251"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}